Haleon missed third-quarter revenue and profit expectations on Thursday, hit by a stronger pound and lower sales of its ...

By Yamini Kalia (Reuters) -Haleon missed third-quarter revenue and profit expectations on Thursday, partly hurt by a stronger ...

Haleon backed its full-year guidance despite lower third-quarter revenue and earnings, although organic revenue growth of 6.1 ...

Oct 29 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and ...

GSK said it is mak­ing its largest man­u­fac­tur­ing in­vest­ment in the US yet, al­lo­cat­ing $800 mil­lion to up­grade its vac­cine pro­duc­tion site in Penn­syl­va­nia. … ...

GSK has made its largest-ever single manufacturing investment in the US. Image credit: Shutterstock/ Golden Shrimp. Following outlays for sites in the UK and Belgium earlier this year, GSK is planning ...

THE ARM FOR THE LANCASTER COUNTY ECONOMY. THIS IS FOR GSK, THE LARGEST INVESTMENT IN MANUFACTURING WE’VE EVER DONE IN THE UNITED STATES. THE $800 MILLION WILL BE USED TO EXPAND GSK’S MARIETTA ...

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

when GSK separated its consumer health business to form an independent company. Their products fall into five categories: oral health (toothpaste), pain relief (Advil), respiratory health (like ...

Is it true that toothpaste can treat pimples? Toothpaste is being touted on social media as a hack to clear acne, soothe burns and whiten fingernails. But dermatologists say products intended for ...

Preliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine Arexvy has potential in younger adults with certain risk factors, potentially positioning the shot ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...